External evaluation of a commercial artificial intelligence-augmented digital auscultation platform in valvular heart disease detection using echocardiography as reference standard
Valentina Roquemen-Echeverri(Oregon Health & Science University), Clara Mosquera-Lopez(Artificial Intelligence in Medicine (Canada)), Bethany Wilson(Oregon Health & Science University), Evan Shalen(Oregon Health & Science University), Peter G. Jacobs(Oregon State University), Quin Denfeld(Oregon Health & Science University), John Halvorson(Oregon Health & Science University), Peter Schulman(Oregon Health & Science University), D. B. Scott(Theranostics (New Zealand)), Tomás Londoño-Murillo(Oregon Health & Science University), Stephen B. Heitner(Brigham and Women's Hospital)
Cited by 10
Related Papers
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
|New England Journal of Medicine|2024|277
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
|Journal of the American College of Cardiology|2023|192
ACUTE‐PHASE RESPONSE AND THE HYPERCOAGULABLE STATE IN PULMONARY TUBERCULOSIS
|British Journal of Haematology|1996|177
An artificial intelligence decision support system for the management of type 1 diabetes
|Nature Metabolism|2020|157